Hemophilia B
Clinical trials for Hemophilia B explained in plain language.
Never miss a new study
Get alerted when new Hemophilia B trials appear
Sign up with your email to follow new studies for Hemophilia B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One-Time gene therapy could slash bleeding in hemophilia b
Disease control OngoingThis study tests a one-time gene therapy for adult men with moderate to severe hemophilia B, a bleeding disorder. The therapy delivers a working gene to help the body produce a clotting protein called Factor IX. Researchers will track how many bleeding episodes participants have …
Matched conditions: HEMOPHILIA B
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
One-Shot gene therapy could free hemophilia b patients from frequent injections
Disease control OngoingThis clinical trial is testing a one-time gene therapy called BBM-H901 for people with hemophilia B, a bleeding disorder caused by low levels of clotting factor IX. The therapy uses a harmless virus to deliver a working copy of the factor IX gene to the liver, so the body can pro…
Matched conditions: HEMOPHILIA B
Phase 2/3 • Sponsor: Shanghai Xinzhi BioMed Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Single gene shot could tame hemophilia b bleeding
Disease control OngoingThis study tests a single intravenous dose of a gene therapy called AskBio009 in up to 30 adults with severe hemophilia B. The therapy delivers a working copy of the factor IX gene to help the body produce its own clotting factor. The main goal is to check safety, but researchers…
Matched conditions: HEMOPHILIA B
Phase 1/2 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug shows promise in reducing bleeding for hemophilia patients
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called fitusiran in people with hemophilia A or B, including those with inhibitors that make standard treatments less effective. The main goal is to see if fitusiran is safe over time and if it reduces bleeding …
Matched conditions: HEMOPHILIA B
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Matched conditions: HEMOPHILIA B
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
No new drug: study tracks bleeding in hemophilia b patients on usual care
Knowledge-focused OngoingThis study follows 11 males with Hemophilia B who already receive regular factor IX therapy to prevent bleeding. Researchers will collect information on bleeding events, treatment use, and quality of life over at least 6 months. No experimental treatment is given; the goal is to …
Matched conditions: HEMOPHILIA B
Sponsor: Regeneron Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Massive survey aims to map haemophilia in Asia-Pacific
Knowledge-focused By invitation onlyThis study collects information from doctors and patient groups across Asia and the Pacific to better understand how haemophilia affects people in the region. No treatments or medications are given; instead, researchers will analyze data on how many people have the condition, how…
Matched conditions: HEMOPHILIA B
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC